Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACASA-TAVI: DOAC vs ASA after TAVI
NCT05035277Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban, rivaroxaban, edoxaban in aortic stenosis (AS), sponsored by Oslo University Hospital. Started Dec 2021; status: completed.
02
Drugs
apixabanrivaroxabanedoxaban
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on NCT05035277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035277.